Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSkin-related reactions are among the reported side effects of Mounjaro (tirzepatide), ranging from mild redness at the injection site to occasional itching elsewhere on the body. The Mounjaro SmPC and NHS guidance both document injection-site reactions as common, while generalised skin symptoms are less frequent but worth knowing about. As a prescription-only medicine, Mounjaro requires clinical assessment before it is prescribed; a GPhC-registered prescriber weighs your individual history, including any skin conditions, before approving treatment. This page draws on the NHS tirzepatide information page and the MHRA-approved Summary of Product Characteristics to give you a factual picture of what the evidence shows, what to monitor, and when to seek medical help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, which randomised 2,539 adults with obesity over 72 weeks and was published in the New England Journal of Medicine, tracked adverse events systematically across all doses. Injection-site reactions appeared in a meaningful proportion of participants, particularly in the first weeks of treatment or after a dose increase. The pattern is consistent with what is seen across subcutaneous injectable medicines more broadly: a new injection site disturbs local tissue, the immune system responds locally, and most reactions settle within a few days.
Beyond the injection site, the SmPC categorises hypersensitivity reactions including urticaria (hives) and pruritus (itching not confined to the injection area) as uncommon, meaning they affect fewer than one in a hundred people. Alopecia — temporary hair thinning — has also been reported, and NICE's appraisal of tirzepatide (TA1026) acknowledges this in its benefit-risk summary. Hair changes in this context are thought to relate to the body's response to rapid weight loss rather than a direct drug effect on hair follicles, and the pattern typically stabilises.
The NICE tirzepatide appraisal (TA1026) concluded the benefit-risk balance is favourable for the licensed population; skin side effects were not a reason to restrict its use, but they do need to be disclosed as part of informed consent, which is why every consultation at nume covers them.
Redness, mild bruising, a raised bump or localised itching at the point of injection are the most frequently reported Mounjaro skin side effects. The pen deposits the medicine just beneath the skin in the subcutaneous fat layer, and the body's local inflammatory response accounts for most of what people see and feel.
Rotating between the three licensed sites (abdomen, thigh, upper arm) and moving the exact spot within each area each week reduces the cumulative load on any patch of skin. The technique set out in your Patient Information Leaflet matters too: pinching the skin correctly, inserting the pen at the right angle and not reusing the same site within a four-week window all make a practical difference.
A simple one-minute check worth building into your weekly routine: once the pen has clicked and you have held it in place for the count recommended in the leaflet, run a finger gently around the site about 10 minutes later. Mild pinkness is expected. A firm lump, significant swelling or spreading redness beyond a couple of centimetres is worth photographing and raising with your prescriber. It will not usually need emergency attention, but it tells your clinical team something useful about how your skin is responding at that dose. More detail on skin-specific reaction patterns is covered on the skin reactions to Mounjaro page.
The vast majority of skin reactions are local, self-limiting and not dangerous. A small number are not. Knowing the difference matters.
Seek medical help promptly if you notice: a spreading rash covering a large area of the body; hives (raised, itchy welts) that appear quickly and are not confined to the injection site; swelling of the lips, tongue, face or throat; dizziness, racing heartbeat or difficulty breathing alongside any skin change. These features together suggest anaphylaxis or a severe hypersensitivity reaction, which needs emergency treatment. Call 999 or go to A&E; do not wait to contact your online pharmacy first.
A localised rash that persists for more than a week, becomes infected (warm, oozing, increasingly painful), or spreads beyond a few centimetres from the injection site should be reviewed by your GP or the prescribing service. Stop the injection in that site and use an alternative one in the meantime.
You can also report any suspected side effects, including unexpected skin reactions, directly to the MHRA through the Yellow Card scheme. This is genuinely useful: post-market safety signals are picked up through Yellow Card reports, and reporting takes about five minutes. The broader picture of Mounjaro side effects, including gastrointestinal effects and the January 2026 MHRA Drug Safety Update on pancreatitis, is covered on the Mounjaro side effects overview.
At nume skin and allergy history is part of the clinical consultation, not an afterthought. A real prescriber, not automated software, reviews every consultation the same day it is submitted. If you have a history of eczema, psoriasis, chronic urticaria or severe drug allergies, that context shapes whether and at what dose tirzepatide is appropriate for you, and our Mounjaro treatment page explains how we approach that assessment in full.
Once treatment is underway, our aftercare team is available seven days a week. If you develop a skin reaction between weekly doses and are unsure whether to continue, the right step is to contact us before your next injection rather than to either press on or stop abruptly without clinical guidance. Our clinical team takes these questions seriously because a skin reaction that looks minor can occasionally be an early sign of something that benefits from prompt review.
If you have questions about specific symptoms you are experiencing, the itchy skin and Mounjaro page goes into more depth on pruritus patterns, and our FAQs cover some of the most common queries. People sometimes search for information about the skinny jab and Mounjaro side effects using that term, and that page brings together what is known about reactions reported in that context. For anything that needs a direct conversation, you can reach the team via the contact page. Treatment at nume begins with a free consultation; our prescribers discuss suitability and side effects, including skin reactions, as a standard part of that process, so you can start with a clear picture of what to expect, including the five Mounjaro side effects most commonly raised by new patients. Start your free consultation when you are ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.